Methadone use in a male with the FMRI premutation and FXTAS

American Journal of Medical Genetics, Part A

Volumn 167, Issue 6, 2015, Pages 1354-1359

  Muzar, Zukhrofi ^a,b   Lozano, Reymundo ^b,c   Schneider, Andrea ^b,c   Adams, Patrick E ^b,c   Faradz, Sultana M H ^a   Tassone, Flora ^b,d   Hagerman, Randi J ^b,c  

^a DIPONEGORO UNIVERSITY   (Indonesia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FMR1 gene; FXTAS; Methadone; Narcotics; Premutation; White matter

Indexed keywords

METHADONE; FMR1 PROTEIN, HUMAN; FRAGILE X MENTAL RETARDATION PROTEIN; NARCOTIC AGENT;

ADULT; ARTICLE; ATAXIA; AUDITORY MEMORY; BEHAVIOR DYSCONTROL SCALE II; CASE REPORT; CAUCASIAN; CORPUS CALLOSUM; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG USE; EXECUTIVE FUNCTION; FMRI GENE; FOLLOW UP; FRAGILE X ASSOCIATED TREMOR ATAXIA SYNDROME; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENOTYPE; HEROIN DEPENDENCE; HUMAN; INTELLECTUAL ASSESSMENT; INTELLIGENCE QUOTIENT; MALE; MEMORY DISORDER; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PONS; PRIORITY JOURNAL; TREATMENT RESPONSE; TREMOR; VISUAL MEMORY; WECHSLER INTELLIGENCE SCALE; WORKING MEMORY; COMPLICATION; DISEASE COURSE; DRUG DEPENDENCE; DRUG EFFECTS; FRAGILE X SYNDROME; GENE EXPRESSION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; WHITE MATTER;

ATAXIA; DISEASE PROGRESSION; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENE EXPRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHADONE; MIDDLE AGED; MUTATION; NARCOTICS; SUBSTANCE-RELATED DISORDERS; TREMOR; WHITE MATTER;

EID: 84929951206     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.37030     Document Type: Article

References (59)

1. Ahn KH, Lyoo IK, Lee HK, Song IC, Oh JS, Hwang J, Kwon J, Kim MJ, Kim M, Renshaw PF. 2004. White matter hyperintensities in subjects with bipolar disorder. Psychiatry Clin Neurosci 58:516-521.
2. Amiri K, Hagerman RJ, Hagerman PJ. 2008. Fragile X-associated tremor/ataxia syndrome: An aging face of the fragile X gene. Arch Neurol 65:19-25.
3. Awad IA, Spetzler RF, Hodak JA, Awad CA, Carey R. 1986. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. I. Correlation with age and cerebrovascular risk factors. Stroke 17:1084-1089.
4. Bae SC, Lyoo IK, Sung YH, Yoo J, Chung A, Yoon SJ, Kim DJ, Hwang J, Kim SJ, Renshaw PF. 2006. Increased white matter hyperintensities in male methamphetamine abusers. Drug Alcohol Depend 81:83-88.
5. Bava S, Frank LR, McQueeny T, Schweinsburg BC, Schweinsburg AD, Tapert SF. 2009. Altered white matter microstructure in adolescent substance users. Psychiatry Res 173:228-237.
6. Bava S, Jacobus J, Thayer RE, Tapert SF. 2013. Longitudinal Changes in White Matter Integrity Among Adolescent Substance Users. Alcohol-Clin Exp Res 37:E181-E189.
7. Bileviciute-Ljungar I, Haglund V, Carlsson J, von Heijne A. 2014. Clinical and radiological findings in methadone-induced delayed leukoencephalopathy. J Rehabil Med 46:828-830.
8. Bokura H, Kobayashi S, Yamaguchi S, Iijima K, Nagai A, Toyoda G, Oguro H, Takahashi K. 2006. Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality: A prospective cohort study. J Stroke Cerebrovasc Dis 15:57-63.
9. Bora E, Yucel M, Fornito A, Pantelis C, Harrison BJ, Cocchi L, Pell G, Lubman DI. 2012. Addict Biol 17:141-148.
10. Boronat MA, Garcia-Fuster MJ, Garcia-Sevilla JA. 2001. Chronic morphine induces up-regulation of the pro-apoptotic Fas receptor and down-regulation of the anti-apoptotic Bcl-2 oncoprotein in rat brain. Br J Pharmacol 134:1263-1270.
11. Buckalew N, Haut MW, Aizenstein H, Rosano C, Edelman KD, Perera S, Marrow L, Tadic S, Venkatraman V, Weiner D. 2013. White matter hyperintensity burden and disability in older adults: Is chronic pain a contributor?. PM R 5:471-480. quiz 480.
12. Caplehorn JR. 1998. Deaths in the first two weeks of maintenance treatment in NSW in 1994: Identifying cases of iatrogenic methadone toxicity. Drug Alcohol Rev 17:9-17.
13. Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR, Jr, Weiner M, DeCarli C. 2010. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol 67:1370-1378.
14. Cerase A, Leonini S, Bellini M, Chianese G, Venturi C. 2011. Methadone-induced toxic leukoencephalopathy: Diagnosis and follow-up by magnetic resonance imaging including diffusion-weighted imaging and apparent diffusion coefficient maps. J Neuroimaging 21:283-286.
15. Chen Y, Tassone F, Berman RF, Hagerman PJ, Hagerman RJ, Willemsen R, Pessah IN. 2010. Murine hippocampal neurons expressing FMR1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet 19:196-208.
16. Coffey SM, Cook K, Tartaglia N, Tassone F, Nguyen DV, Pan R, Bronsky HE, Yuhas J, Borodyanskaya M, Grigsby J, Doerflinger M, Hagerman PJ, Hagerman RJ. 2008. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A 146A:1009-1016.
17. Corre J, Pillot J, Hilbert G. 2013. Methadone-induced toxic brain damage. Case Rep Radiol 2013:602981.
18. de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J, Breteler MM. 2000. Cerebral white matter lesions and cognitive function: The Rotterdam Scan Study. Ann Neurol 47:145-151.
19. de Lau LM, Smith AD, Refsum H, Johnston C, Breteler MM. 2009. Plasma vitamin B12 status and cerebral white-matter lesions. J Neurol Neurosurg Psychiatry 80:149-157.
20. Debette S, Markus HS. 2010. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: Systematic review and meta-analysis. BMJ 341:c3666.
21. Fields RD. 2008. White matter in learning, cognition and psychiatric disorders. Trends Neurosci 31:361-370.
22. Filipovic-Sadic S, Sah S, Chen L, Krosting J, Sekinger E, Zhang W, Hagerman PJ, Stenzel TT, Hadd AG, Latham GJ, Tassone F. 2010. A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem 56:399-408.
23. Garcia-Arocena D, Hagerman PJ. 2010. Advances in understanding the molecular basis of FXTAS. Hum Mol Genet 19:R83-R89.
24. Garde E, Mortensen EL, Krabbe K, Rostrup E, Larsson HBW. 2000. Relation between age-related decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: a longitudinal study. Lancet 356:628-634.
25. Garde E, Mortensen EL, Rostrup E, Paulson OB. 2005. Decline in intelligence is associated with progression in white matter hyperintensity volume. J Neuro Neurosurg Psychiatry 76:1289-1291.
26. Godin O, Dufouil C, Maillard P, Delcroix N, Mazoyer B, Crivello F, Alpérovitch A, Tzourio C. 2008. White matter lesions as a predictor of depression in the elderly: The 3C-Dijon study. Biol Psychiatry 63:663-669.
27. Godin O, Tzourio C, Maillard P, Mazoyer B, Dufouil C. 2011. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: The Three-City (3C)-Dijon Magnetic Resonance Imaging Study. Circulation 123:266-273.
28. Gouw AA, Van der Flier WM, van Straaten EC, Barkhof F, Ferro JM, Baezner H, Pantoni L, Inzitari D, Erkinjuntti T, Wahlund LO, Waldemar G, Schmidt R, Fazekas F. Scheltens P; LADIS Study Group. 2006. Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: The LADIS study. J Neurol 253:1189-1196.
29. Hagerman PJ, Hagerman RJ. 2004. The fragile-X premutation: A maturing perspective. Am J Hum Genet 74:805-816.
30. Hagerman R, Hagerman P. 2013. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol 12:786-798.
31. Hamlin AA, Sukharev D, Campos L, Mu Y, Tassone F, Hessl D, Nguyen DV, Loesch D, Hagerman RJ. 2012. Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet A 158A:1304-1309.
32. Hoem G, Raske CR, Garcia-Arocena D, Tassone F, Sanchez E, Ludwig AL, Iwahashi CK, Kumar M, Yang JE, Hagerman PJ. 2011. CGG-repeat length threshold for FMR1 RNA pathogenesis in a cellular model for FXTAS. Hum Mol Genet 20:2161-2170.
33. Ikram MA, Vernooij MW, Vrooman HA, Hofman A, Breteler MM. 2009. Brain tissue volumes and small vessel disease in relation to the risk of mortality. Neurobiol Aging 30:450-456.
34. Kerber KA, Whitman GT, Brown DL, Baloh RW. 2006. Increased risk of death in community-dwelling older people with white matter hyperintensities on MRI. J Neurol Sci 250:33-38.
35. Kogan CS, Turk J, Hagerman RJ, Cornish KM. 2008. Impact of the Fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated Tremor/Ataxia syndrome: A controlled study. Am J Med Genet B Neuropsychiatr Genet 147B:859-872.
36. Kuller LH, Arnold AM, Longstreth WT, Jr, Manolio TA, O'Leary DH, Burke GL, Fried LP, Newman AB. 2007. White matter grade and ventricular volume on brain MRI as markers of longevity in the cardiovascular health study. Neurobiology of Aging 28:1307-1315.
37. Lagopoulos J, Hermens DF, Hatton SN, Tobias-Webb J, Griffiths K, Naismith SL, Scott EM, Hickie IB. 2013. Microstructural white matter changes in the corpus callosum of young people with Bipolar Disorder: A diffusion tensor imaging study. PLoS ONE 8:e59108.
38. Leehey MA, Berry-Kravis E, Min SJ, Hall DA, Rice CD, Zhang L, Grigsby J, Greco CM, Reynolds A, Lara R, Cogswell J, Jacquemont S, Hessl DR, Tassone F, Hagerman R, Hagerman PJ. 2007. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord 22:203-206.
39. Leehey MA, Legg W, Tassone F, Hagerman R. 2011. Fibromyalgia in fragile X mental retardation 1 gene premutation carriers. Rheumatology (Oxford) 50:2233-2236.
40. Lin WC, Chou KH, Chen CC, Huang CC, Chen HL, Lu CH, Li SH, Wang YL, Cheng YF, Lin CP. 2012. White matter abnormalities correlating with memory and depression in heroin users under methadone maintenance treatment. PLoS ONE 7:e33809.
41. Lyoo IK, Streeter CC, Ahn KH, Lee HK, Pollack MH, Silveri MM, Nassar L, Levin JM, Sarid-Segal O, Ciraulo DA, Renshaw PF, Kaufman MJ. 2004. White matter hyperintensities in subjects with cocaine and opiate dependence and healthy comparison subjects. Psychiatry Res 131:135-145.
42. Mintzer MZ, Stitzer ML. 2002. Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend 67:41-51.
43. Oksala NK, Oksala A, Pohjasvaara T, Vataja R, Kaste M, Karhunen PJ, Erkinjuntti T. 2009. Age related white matter changes predict stroke death in long term follow-up. J Neurol Neurosurg Psychiatry 80:762-766.
44. Peles E, Schreiber S, Naumovsky Y, Adelson M. 2007. Depression in methadone maintenance treatment patients: Rate and risk factors. J Affect Disord 99:213-220.
45. Prasad K, Wiryasaputra L, Ng A, Kandiah N. 2011. White matter disease independently predicts progression from mild cognitive impairment to Alzheimer's disease in a clinic cohort. Dement Geriatr Cogn Disord 31:431-434.
46. Primerano B, Tassone F, Hagerman RJ, Hagerman P, Amaldi F, Bagni C. 2002. Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA 8:1482-1488.
47. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Jolles J, Koudstaal PJ, Hofman A, Breteler MM. 2005. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 128:2034-2041.
48. Prosser J, Cohen LJ, Steinfeld M, Eisenberg D, London ED, Galynker II. 2006. Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment. Drug Alcohol Depend 84:240-247.
49. Salgado RA, Jorens PG, Baar I, Cras P, Hans G, Parizel PM. 2010. Methadone-induced toxic leukoencephalopathy: MR imaging and MR proton spectroscopy findings. AJNR Am J Neuroradiol 31:565-566.
50. Schlaepfer TE, Lancaster E, Heidbreder R, Strain EC, Kosel M, Fisch HU, Pearlson GD. 2006. Decreased frontal white-matter volume in chronic substance abuse. Int J Neuropsychopharmacol 9:147-153.
51. Sellier C, Freyermuth F, Tabet R, Tran T, He F, Ruffenach F, Alunni V, Moine H, Thibault C, Page A, Tassone F, Willemsen R, Disney MD, Hagerman PJ, Todd PK, Charlet-Berguerand N. 2013. Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep 3:869-880.
52. Shen Y, Wang E, Wang X, Lou M. 2012. Disrupted Integrity of White Matter in Heroin-addicted Subjects at Different Abstinent Time. J Addict Med 6:172-176.
53. Tassone F, Hagerman RJ, Loesch DZ, Lachiewicz A, Taylor AK, Hagerman PJ. 2000. Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. Am J Med Genet 94:232-236.
54. Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. 2008. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile x (FMR1) gene in newborn and high-risk populations. J Mol Diagn 10:43-49.
55. Voineskos AN, Foussias G, Lerch J, Felsky D, Remington G, Rajji TK, Lobaugh N, Pollock BG, Mulsant BH. 2013. Neuroimaging evidence for the deficit subtype of schizophrenia. JAMA Psychiatry 70:472-480.
56. Wang GY, Wouldes TA, Kydd R, Jensen M, Russell BR. 2014. Neuropsychological performance of methadone-maintained opiate users. J Psychopharmacol 28:789-799.
57. Winarni TI, Chonchaiya W, Sumekar TA, Ashwood P, Morales GM, Tassone F, Nguyen DV, Faradz SM, Van de Water J, Cook K, Hamlin A, Mu Y, Hagerman PJ, Hagerman RJ. 2012. Immune-mediated disorders among women carriers of fragile X premutation alleles. Am J Med Genet A 158A:2473-2481.
58. Yücel M, Zalesky A, Takagi MJ, Bora E, Fornito A, Ditchfield M, Egan GF, Pantelis C, Lubman DI. 2010. White-matter abnormalities in adolescents with long-term inhalant and cannabis use: A diffusion magnetic resonance imaging study. J Psychiatry Neurosci 35:409-412.
59. Zheng JJ, Delbaere K, Close JC, Sachdev P, Wen W, Brodaty H, Lord SR. 2012. White matter hyperintensities are an independent predictor of physical decline in community-dwelling older people. Gerontology 58:398-406.